North America Sterile Injectables Market Size Analysis, 2018-2028
|REPORT ID: BKR646-NA||Domain: Healthcare||Published Date: April 2018|
North America Sterile Injectables Market Size Analysis
North America sterile injectables market size is expected to register a CAGR of above 4.6% during the forecast period – with industry players accounting for the majority of the market share.
Access Global Sterile Injectables Market Report and Data with Special Focus on 27+ countries: https://bekryl.com/industry-trends/sterile-injectable-market-size-analysis
The industry in the region is highly mature compared to other regions, however, is poised to offers stable revenue opportunity to the engaged companies. Stringent regulations has helped in creating favorable business scenario in the region. Furthermore, research and development spending is comparatively higher in the region. Expected patent expiry of large number of biologics will pave way for entry of new players, and as a result, will boost the overall production capacity.
North America sterile injectables market is characterized by high margin segment with attractive investment proposition. Quality is the main parameter in the region. Stringent regulatory compliances has led to elimination of some of the manufacturing companies from regional picture. Some of the companies have production facilities older than 20 years. As such, these companies are expected to revive the production facilities in the region in order to ensure stable market growth.
Insight#1: South-West Region to Witness Highest Sales of Sterile Injectables
U.S. will account for 91% North America sterile injectables market share in 2018. Much of the production and sales will be concentrated to South-West Region. U.S. has over 16.7% healthcare expenditure along with presence of large number of pharmaceuticals – creating favorable business environment for manufacturers and suppliers.
Insight#2: Companies are focusing on Plant Expansion in North Sterile Injectables Market
Leading players are focusing on expansion of production capacity to meet the growing demand for sterile injectables across North America and South America. Recently, in 2016, Fresenius Kabi announced to invest US$ 250 million in next 10 years to expand its production capacity at Melrose Park Site. Another company, Glenmark announced its plan to invest US$ 26 million in new manufacturing site in North Carolina, U.S.
Insight#3: Small Molecules to Gain Higher Traction in North America Sterile Injectables Market
Expected patent expiry of biologics will create lucrative business opportunity for companies engaged in small molecules. The segment will register over 750 basis point gain by the end of forecast period. Much of its therapeutic application will be in oncology followed by cardiovascular segment.
North America Sterile Injectables Market Size and Forecast: Competition Landscape
Some leading sterile injectables market players in North America are Novartis AG, Gilead, Sciences, Inc., Merck & Co., Inc., Sanofi, Pfizer Inc., Baxter International Inc., and GlaxoSmithKline plc. AstraZeneca, Johnson & Johnson Services, Inc., and Novo Nordisk A/S
North America Sterile Injectables Market Industry Segmentation
(Download Sample to Access Complete TOC, Research Framework and Strategic Insights on North America region)
By Product Type:
- Small Molecules
- Large Molecules
By Therapeutic Application:
- Cardiovascular Diseases
- Central Nervous Systems
- Infectious Disorders
By Route of Administration:
- Other Route of Administration
By Drug Type:
- Monoclonal Antibodies (mAbs)
- Peptide Hormones
- Blood Factors
- Peptide Antibiotics
By Distribution Channel:
- Drug Stores
- Online e-Commerce*